Medpace: 3 Key Takeaways for Long-Term Investors
Cancellations now stem from clinical failures rather than funding shortages, signaling a healthier market for contract research.
Medpace reported record net new business awards in Q3 2026, indicating strong client demand for clinical trial management services. CEO August James Troendle highlighted that cancellations are now primarily due to product failures, rather than client capital constraints. Management is prioritizing execution quality over competitive pricing to protect long-term project margins.
Written by urgent.news from Motley Fool's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
